We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Non-Invasive Prostate Cancer Test Developed Using Exosomal RNA

By LabMedica International staff writers
Posted on 11 May 2016
Print article
Image: A histopathology of prostate cancer showing multiple poorly formed glands with ill-defined lumina and/or incomplete nuclear complement, Gleason score 3+4 = 7 (Photo courtesy of European Urology).
Image: A histopathology of prostate cancer showing multiple poorly formed glands with ill-defined lumina and/or incomplete nuclear complement, Gleason score 3+4 = 7 (Photo courtesy of European Urology).
The current screening paradigm for prostate cancer faces challenges that lead to unnecessary biopsies and, ultimately, overtreatment. The disadvantage of Prostate-Specific Antigen (PSA) testing is lack of specificity for prostate cancer resulting in both false positive and false negative results.

Furthermore, PSA does not discriminate between high- and low-grade prostate cancers. Low-grade disease could remain indolent for a long period of time and typically does not require aggressive treatment. There is a need for pre-biopsy diagnostic tools that can accurately identify high-grade prostate cancer that requires more immediate intervention.

A team of Urologists led by those at Columbia University (New York, NY, USA) used reverse-transcriptase polymerase chain reaction (PCR), to compare the urine exosome gene expression assay with biopsy outcomes in 499 patients with prostate-specific antigen (PSA) levels of 2 to 20 ng/mL. The derived prognostic score was then validated in 1,064 patients from 22 community practice and academic urology clinic sites in the USA. Eligible participants included indolent prostate cancer (PCA)-free men, 50 years or older, scheduled for an initial or repeated prostate needle biopsy due to suspicious digital rectal examination (DRE) findings and/or PSA levels (limit range, 2.0 to 20.0 ng/mL).

The teams used the novel urine-based prostate cancer liquid biopsy test, ExoDx Prostate(IntelliScore) (Exosome Diagnostics, Inc, Cambridge, MA, USA) in non-DRE, first-catch urine samples. The test then analyzes the urine for three biomarkers on exosomal ribonucleic acid (exoRNA) that are expressed in men with high-grade prostate cancer. In 255 men in the training target population (median age 62 years and median PSA level 5.0 ng/mL, and initial biopsy), the urine exosome gene expression assay plus standard of care (SOC) was associated with improved discrimination between Gleason score (GS7) or greater and GS6 and benign disease. Independent validation in 519 patients urine exosome gene expression assay plus SOC was superior to SOC. Using a predefined cut point, 138 of 519 (27%) biopsies would have been avoided, missing only 5% of patients with dominant pattern 4 high-risk GS7 disease.

James McKiernan, MD, the lead author said, “The possibility of a ‘liquid biopsy’ that does not involve an invasive procedure and may be as simple as a urine test, has the potential to change the way we approach the most common cancer in men. If the predictive accuracy of the assay can be validated in further studies, it has the potential to replace the PSA test once and for all.” The study was published on March 31, 2016, in the journal JAMA Oncology.

Related Links:
Columbia University
Exosome Diagnostics
Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
Total 25-Hydroxyvitamin D₂ & D₃ Assay
New
Coagulation Analyzer
CS-2400

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.